Notice of Information: Temporary Extension of Eligibility for NHLBI K24 Applicants Due to COVID-19
Notice Number:
NOT-HL-22-007

Key Dates

Release Date:

January 13, 2022

Related Announcements

NOT-HL-15-261 - Notice of Revised NHLBI Submission Policies for PA-14-047 “Midcareer Investigator Award in Patient-Oriented Research (Parent K24)"
PA-20-186 - Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed)
PA-20-193 - Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required)

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

This Notice announces a temporary change in NHLBI-specific requirements for Individual Eligibility for a Midcareer Investigator Award in Patient-Oriented Research (K24).

The extension to individual eligibility described herein will be in effect for applications due on February 12, 2022 through November 12, 2023 submitted to the following funding opportunity announcements (and any reissues published before November 12, 2023):

Individual Eligibility: Under normal circumstances, NHLBI has accepted new K24 applications from associate or full professors within 10 years of their appointment as an associate professor at the time of application (See NOT-HL-15-261). Due to disruptions in professional pursuits and personal lives experienced during the COVID-19 pandemic, NHLBI will temporarily extend the period of individual eligibility to 12 years beyond an applicant’s appointment as an associate professor.

Inquiries

Please direct all inquiries to:

Scientific Program Contact:
Susan Shero, Ph.D.
(301) 496-1051
Email: [email protected]

Grants Management Contact:
Taryn Cobb
Phone: (301) 827-8025
Email: [email protected]